ALOX5AP itself lacks enzymatic activity and instead serves to enhance 5-lipoxygenase (LO) activity [9]. In the first step of the 5-LO pathway, 5-LO, in co-operation with ALOX5AP, converts arachidonic acid to leukotriene (LT) A4 (LTA4). Subsequently, LTA4 can be converted to LTB4 by LTA4 hydrolase and/or converted to LTC4 by LTC4 synthase; LTC4 is then cleaved into LTD4 and LTE4 [10]. The products of the
5-LO pathway, including LTC4, LTD4, LTE4 and LTB4, are known to play an important roles in allergic diseases such as asthma, allergic rhinitis and atopic dermatitis [11]. Many studies have analysed the genes in the 5-LO pathway for possible associations with asthma-susceptibility. For example, Choi et al.
[12] found that the ALOX5-[G-C-G-A] haplotype influences the development Bortezomib of aspirin-intolerant asthma in a Korean population. The same study also showed that leukotrienes may play a role in the pathophysiology of asthma in a Korean population. Moreover, it has been reported that patients with asthma express ALOX5AP at higher levels than the general population [13]. Another study has shown that ALOX5AP promotes asthma either on its own and/or via its interactions with genes in the find more leukotriene pathway [14]. In addition, ALOX5AP has been reported to play a critical role in the pathogenesis of various cardiovascular diseases [15, 16]. Therefore, inhibitors of ALOX5AP are likely to be clinical beneficial in allergic asthma and various cardiovascular diseases [17]. However, although it has been proposed that ALOX5AP may play a potentially causative role in asthma, its relationship with lung Rebamipide function in a general population has not yet been examined [18]. In this study, the influence of genetic variation in the ALOX5AP gene on the lung functions of a healthy and general population was evaluated. Subjects. The data used in this study were obtained from the Korea Association Resource (KARE) project in the Korean
Genome Epidemiology Study (KoGES), which began in 2001, was conducted by the Korea National Institute of Health (KNIH) [19]. The KoGES study was a cross-sectional analysis of 5018 and 5020 subjects from urban (Ansan) and rural (Ansung) communities in Korea, respectively. The ages of the participants ranged from 40 to 69 years. After a quality control process had been implemented, 8842 subjects in total were selected. General characteristics (age, sex, area, height, etc.), smoking status, medical history and current medications were collected from participants by questionnaires and the assessments were managed by trained interviewer. The participants have been examined every 2 years and 6-year follow-up study was currently completed. The procedures were conducted according to institutional guidelines and approved by an institutional review committee.